ESRRG and esophageal squamous cell carcinoma: In esophageal squamous cell carcinoma, the administration of the estrogen-related receptor gamma(ESRRG) specific agonist DY131 downregulate PKM2 expression with a marked suppression of glycolytic activity and lactate production, synergistically augmenting the efficacy of anti-PD-1 treatment60.